EP1309571A1 - Nichtsteroidale entzündungshemmer - Google Patents

Nichtsteroidale entzündungshemmer

Info

Publication number
EP1309571A1
EP1309571A1 EP01960536A EP01960536A EP1309571A1 EP 1309571 A1 EP1309571 A1 EP 1309571A1 EP 01960536 A EP01960536 A EP 01960536A EP 01960536 A EP01960536 A EP 01960536A EP 1309571 A1 EP1309571 A1 EP 1309571A1
Authority
EP
European Patent Office
Prior art keywords
methyl
hydroxy
benzoxazin
amino
trifluoromethylvaleroylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01960536A
Other languages
German (de)
English (en)
French (fr)
Inventor
Stefan Jaroch
Manfred Lehmann
Norbert Schmees
Bernd Buchmann
Hartmut Rehwinkel
Peter Droescher
Werner Skuballa
Konrad Krolikiewicz
Hartwig Hennekes
Heike Schäcke
Arndt Schottelius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP1309571A1 publication Critical patent/EP1309571A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Definitions

  • the present invention relates to the use of non-steroidal compounds for the production of medicaments for the treatment of inflammation, selected compounds and their production processes.
  • non-steroidal compounds In addition to a large number of steroid compounds that bind well to the glucocorticoid receptor and have an anti-inflammatory effect (glucocorticoids), non-steroidal compounds are known that bind to the glucocorticoid receptor, but for which no anti-inflammatory effect has so far been shown [cf. Nature Medicin 4 (1998) 92, Mol. Pharmacol. 52 (1997) 571]. Furthermore, non-steroidal compounds have been described which are derived from steroidal compounds, have affinity for the glucocorticoid receptor and are likely to have an anti-inflammatory effect mediated by receptors [J. Med. Chem. 36, (1993), 3278-3285]. However, these compounds showed no advantages over steroidal glucocorticoids in animal experiments, i.e. the anti-inflammatory effects of metabolic effects, e.g. Suppression of adrenal function to separate.
  • non-steroidal compounds which have a high gestagenic activity.
  • the document states that some of the compounds claimed also have activity on the glucocorticoid and / or mineral corticoid receptor.
  • no connections are specifically mentioned in this context, nor are test results disclosed.
  • Compounds which have selectivity with regard to the effects mentioned are advantageous in terms of industrial applicability.
  • phenol derivatives which have an active dissociation between the anti-inflammatory activity and the undesirable metabolic side effects are known as non-steroidal anti-inflammatory agents.
  • the object was therefore to provide new non-steroidal anti-inflammatories which show at least as good or better dissociation of action than the compounds of the prior art.
  • Nonsteroidal compounds have now been found which bind well to the glucocorticoid receptor and, through this binding, bring about an anti-inflammatory effect. In the experiment, these compounds show significantly better or at least equally good dissociations of effects between anti-inflammatory and undesirable effects and are superior to the previously described, non-steroidal glucocorticoids or at least have an equally good effect.
  • R and R are the same or different and represent a hydrogen atom, a C 5 -C 5 alkyl group or, together with the C atom of the chain, a ring with a total of 3-7 links, R represents a straight-chain or branched C 1 -C 5 -alkyl group or a straight-chain or branched, partially or completely fluorinated O, -C 5 alkyl group,
  • R 4 to R 8 are identical or different from one another and are a hydrogen atom, a halogen atom, a cyano group, a nitro group, a COOR 9 group, where R 9 is a hydrogen atom, a straight-chain or branched
  • Ci-C ⁇ alkyl group or a benzyl group a CONR 10 group, where R 10 represents a hydrogen atom or a straight-chain or branched C 1 -C 5 alkyl group, an NHR 11 group where R 11 represents a hydrogen atom, a straight-chain or branched Ci-Cs-alkyl group, a straight-chain or branched partially or fully fluorinated C ⁇ -C 5 alkyl group, a C1-C5-acyl group, a -S ( 2 - (C ⁇ -C 5 ) alkyl group or an optionally by halogen or a C ⁇ -C 5 alkyl group substituted -SO 2 phenyl group, a straight-chain or branched Ci-C ⁇ -alkyl group, a straight-chain or branched C 2 -C 5 alkenyl group, a straight-chain or branched C2-C5-alkynyl group, a straight-chain or branched , partially or
  • Mean acyl group, an aryl radical or a heteroaryl radical, R 4 and R 5 together with the two carbon atoms of ring A represent a saturated or unsaturated carbocyclic ring with a total of 5-7 members, Ar represents a ring system selected from the group of general sub-formulas 1 or 2,
  • radicals X 3a , X 3b , X 4 , X 6 , X ? (in sub-formula 1) and Y 4 , Y 5 , Y 7 , Y 8 (in sub-formula 2) are the same or different and represent a hydrogen atom, a straight-chain or branched C, -C 5 -alkyl group, or a straight-chain or branched, partially or fully fluorinated C, -C 5 alkyl group, the radicals X, X.
  • X (in sub-formula 1) or Y, Y, Y (in sub-formula 2) are also the same or different and are a hydrogen atom, a halogen atom, a hydroxy group, a C.-, C- 5 alkoxy group or a CC 5 alkanoyloxy group mean, and their racemates or stereoisomers present separately, and optionally their physiologically tolerable salts.
  • the compounds of general formula I according to the invention can exist as different stereoisomers due to the presence of asymmetry centers. Both the racemates and the separately present stereoisomers belong to the subject of the present invention.
  • a particular subject of the present invention are the isomers which rotate the plane of polarized light in such a way that they are referred to as (+) compounds.
  • the substituents defined as groups or radicals in the compounds of the general formula I can each have the following meanings.
  • the d-Cs-alkyl groups R 1 , R 2 , R 3 , R 4 , R 5 , R 12 , X n , Y ° can be straight-chain or branched and for a methyl, ethyl, n-propyl, iso- Propyl, n-butyl, isobutyl, tert-butyl or n-pentyl, 2,2-dimethylpropyl, 2-methylbutyl or 3-methylbutyl group.
  • a methyl or ethyl group is preferred.
  • R 1 and R 2 together with the carbon atom of the chain form a 3-7 membered ring, this can optionally be substituted by 1-2 oxygen atoms and for example a cyclopropyl, butyl, pentyl hexyl or heptyl ring , his.
  • the partially or fully fluorinated alkyl groups mentioned above are suitable.
  • the trifluoromethyl group and the pentafluoroethyl group are preferred.
  • the substituents of the phenyl ring A can independently of one another have the meanings defined in the claims, such as a hydrogen atom, a halogen atom, a cyano group, a nitro group, an NHR 1 group where R 11 is a hydrogen atom, a straight-chain or branched dC ⁇ alkyl group, a straight-chain one or branched partially or fully fluorinated d-Cs-alkyl group, a Ci-C ⁇ -acyl group, a
  • R 4 and R 5 together with the two carbon atoms of ring A can mean a saturated or unsaturated carbocyclic ring with a total of 5-7 members, such as, for example, indane, naphthalene, tetrahydronaphthalene, benzocycloheptane.
  • An object of the invention is the use of the compounds of the general formula I in which R 4 to R 8 are identical or different from one another and are a hydrogen atom, a halogen atom, a cyano group, a nitro group, a COOR 9 group where R 9 is a hydrogen atom, a straight-chain or branched C 1 -C 5 -alkyl group or a benzyl group, a CONR 10 group, where R 10 represents a hydrogen atom or a straight-chain or branched C 1 -C 5 -alkyl group, an NHR 11 group, where R 11 represents a Hydrogen atom, a straight-chain or branched C 1 -C 5 -alkyl group, a straight-chain or branched partially or completely fluorinated C 1 -C 5 -alkyl group, a Ci-Cs-acyl group, a -SO 2 - (-C-Cs) alkyl group or an optionally by halogen or a Ci
  • halogen atom or halogen means a fluorine, chlorine, bromine or iodine atom.
  • a fluorine, chlorine or bromine atom is preferred.
  • a C ⁇ -Cs alkenyl group there are, for example, a vinyl, 2-substituted vinyl group, 1-propenyl, 2-propenyl, 2- or 3-substituted 2- Propenyl group, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 1-methyl-1-butenyl, 2 -Methyl-1-butenyl, 3-methyl-1-butenyl group into consideration.
  • the alkenyl groups which carry the double bond in the 1- or 2-position are preferred.
  • the methyl or the ethyl group are particularly suitable as substituents for the vinyl group or the propenyl group.
  • a C2-C 5 alkynyl group is, for example, an ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-methyl-1-butynyl, 4-methyl-1-butynyl or 1-pentynyl group understood.
  • the alkynyl groups which have a triple bond in the 1- or 2-position are preferred.
  • Ci-Cs-acyl group means, for example, a formyl, acetyl, propionyl, n-butyroyl, 2-methylpropionyl, n-valeroyl, 2-methylbutyroyl, 3-methylbutyroyl or a pivaloyl group.
  • a sulfonyl (C -Cs) alkyl group R 11 means , for example, a methylsulfonyl or an ethylsulfonyl group.
  • sulfonylphenyl group R 11 which is optionally substituted by halogen or a Ci-Cs-alkyl group
  • the free valence of the sulfonyl group is attached to the nitrogen atom of the NHR 11 group.
  • Aryl means a phenyl group or a substituted phenyl group
  • Halogen atoms which are cyano, nitro,
  • Ci-Cs alkoxy amino, hydroxyl, carboxy and Ci-Cs alkanoyl groups, branched and unbranched C 5 -C 5 alkyl groups, branched and unbranched Ci-Cs alkyl groups, which can be partially or completely fluorinated, in Question.
  • Heteroaryl comprises aromatic heterocyclic 5- and 6-rings, the ring 1-3 further heteroatoms from the group oxygen, nitrogen, or sulfur can contain. Heterocyclic five-membered rings are preferred. Furyl, thienyl, pyridyl, thiazolyl, oxazolyl, oxadiazolyl, imidazolyl may be mentioned in particular.
  • the heteroaryl groups can optionally be substituted by branched and unbranched Ci-Cs-alkyl groups, branched and unbranched Ci-Cs-alkyl groups which can be fluorinated and / or halogen atoms.
  • hydroxyl groups possible for the radicals X ⁇ , Y ° can optionally be present as ethers or esters, which are defined below:
  • alkyl groups in particular a methyl or ethyl group, are suitable as the Ci-Cs-alkyl group for etherifying hydroxy groups.
  • a formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl or iso-valeryl or pivaloyl group, preferably an acetyl group, are suitable as the CrC 5 alkanoyl group for the esterification of hydroxyl groups.
  • alkanoyl groups preferably again an acetyl group, or a benzoyl, toluoyl, phenylacetyl, acryloyl, cinnamoyl or cyclohexylcarbonyl group may be mentioned, for example, as the Ci-Cs-acyl group for the esterification of hydroxy groups.
  • the d-Cs-alkanoyloxy group for X 4 , X 6 > X 7 , Y 4 , Y 5 , Y 7 or Y 8 is a formyloxy, acetoxy, propionyloxy, butyryloxy, iso-butyryloxy, valeryloxy or iso -Valeryloxy distr into consideration, preferably an acetoxy group.
  • Non-steroidal compounds as such with a mixed profile of gestagenic and androgenic activity in different forms are already the subject of WO 98/54159.
  • the compounds of the general formula I according to claim 1 to be used according to the present patent application for the preparation of medicaments with anti-inflammatory activity fall within the scope of the general formula contained in WO 98/54159, but are not preferred there as a group or disclosed directly as compounds. They are thus new and, because of the anti-inflammatory effect found for them, dissociated from undesirable metabolic or other effects, also meet the patenting requirement of the inventive step.
  • Undesired effects / effects in the sense of the present invention are metabolic effects or bonds to other steroid receptors.
  • the present invention relates to the following compounds.
  • (+) 6- [4- (Indan-4'-yl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] -4-methyl-2,3-benzoxazin-1-one 6- [4- (5th -Fluoro-2-vinylphenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] -4-methyl-2,3-benzoxazin-1 -one
  • (+) - 6- [4- (2,5-Difluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] -4-methyl-2,3-benzoxazin-1 -one 6- [4- (2nd , 6-difluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] -4-methyl-2,3-benzoxazin-1 -one
  • (+) - 6- [4- (4-Fluoro-2-trifluoromethylphenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroyl] amino-4-methyl-2,3-benzoxazin-1- on 6- [4- (5-fluoro-2-trifluoromethylphenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroyl] amino-4-methyl-2,3-benzoxazin-1-one
  • (+) - 6- [3- ⁇ 1- (2-Chloro-4-fluorophenyl) cyclobutyl ⁇ -2-hydroxy-2-trifluoromethylpropionyl] amino-4-methyl-2,3-benzoxazin-1- on 6- [3- ⁇ 1- (2-chloro-5-fluorophenyl) cyclopropyl ⁇ -2-hydroxy-2-trifluoromethylpropionyl] - amino-4-methyl-2,3-benzoxazin-1-one
  • (+) - 6- [3- ⁇ 1- (2-Chloro-5-fluorophenyl) cyclobutyl ⁇ -2-hydroxy-2-trifluoromethylpropionyl] amino-4-methyl-2,3-benzoxazin-1- on 6- [3- ⁇ 1- (2,4-dichlorophenyl) cyclopropyl ⁇ -2-hydroxy-2-trifluoromethylpropionyl] - amino-4-methyl-2,3-benzoxazin-1-one
  • (+) - 6- [3- ⁇ 1- (2,4-dichlorophenyl) cyclopropyl ⁇ -2-hydroxy-2-trifluoromethylpropionyl] - amino-4-methyl-2,3-benzoxazin-1 -one
  • (+) - 6- [3- ⁇ 1- (2,5-difluorophenyl) cyclopropyl ⁇ -2-hydroxy-2-trifluoromethylpropionylamino] -4-methyl-2,3-benzoxazin-1-one 6- [ 3- ⁇ 1 - (2,3,5-Thfluorophenyl) cyclopropyl ⁇ -2-hydroxy-2-trifluoromethylpropionylamino] -4-methyl-2,3-benzoxazin-1-one
  • (+) - 6- [3- ⁇ 1- (2,3,5-Trifluorophenyl) cyclobutyl ⁇ -2-hydroxy-2-trifluoromethylpropionylamino] -4-methyl-2,3-benzoxazin-1-one 6 - [3- ⁇ 1- (2-bromophenyl) -cyclopropyl ⁇ -2-hydroxy-2-trifluormethylpropionylamino] -
  • (+) - 6- [4- (2-Bromo-3-hydroxyphenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] -4-methyl-2,3-benzoxazin-1-one 6- [4- (2,3-difluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylcaproylamino] -4-methyl-2,3-benzoxazin-1-one
  • a special aspect of the present invention are the 2,3-benzoxazin-1-ones listed above.
  • Another aspect of the present invention are the compounds listed above, whose 2,3-benzoxazin-1-one bears a methyl group in the 3-position.
  • the compounds of the general formula I are present as salts, this can be, for example, in the form of the hydrochloride, sulfate, nitrate, phosphate, pivalate, maleate, fumarate, tartrate, benzoate, mesylate, citrate or succinate.
  • the compounds according to the invention can be separated into the pure, optically active forms by methods of racemate separation familiar to the person skilled in the art.
  • the racemic mixtures can be chromatographed Separate into the pure isomers on a self-optically active carrier material (CHIRALPAK AD®).
  • CHIRALPAK AD® self-optically active carrier material
  • esterify the free hydroxyl group in a racemic compound of the general formula I with an optically active acid and to separate the resulting diastereoisomeric esters by fractional crystallization or chromatographically and to saponify the separated esters to give the optically pure isomers.
  • mandelic acid, camphorsulfonic acid or tartaric acid can be used as the optically active acid.
  • compounds which have been prepared by one of the processes below and in which A is a substituted aromatic ring can be selectively substituted on this aromatic radical by known processes. Examples of this process are the catalytic hydrogenation of multiple bonds, nitration and halogenation. Halogen and nitro substitutions also offer the possibility of further modifications.
  • aryl bromides can be reacted with boron, tin or zinc reagents with palladium catalysis in the manner known to those skilled in the art.
  • Nitro compounds can be reduced to aniline derivatives, for example hydrogenolytically, or with metals such as. eg iron or zinc. After diazotization, the aniline derivatives can be reacted in a known manner, for example in the sense of Sandmeyer reactions.
  • R 1 and R 2 have the meanings given in formula I is either optionally esterified with a compound of the general formula (R 12 ) 3 SiR 3 (III)
  • R 3 has the meaning given in the general formula I and R 12 represents a Ci-Cs-alkyl group, in the presence of a catalyst or with an alkyl metal compound, for example a Grignard reagent or a lithium alkyl, to give a compound of the formula IV
  • R 13 represents a hydrogen atom or a C1-C5 acyl group and Ar has the meaning given in the general formula I, reacted, the radical R 13 then being split off to give a
  • R 13 represents a hydrogen atom or a C 5 -C 5 acyl group and Ar has the meaning given in the general formula I, optionally after activation of the acid function by, for example, conversion into the acid chloride, the radical R 13 then being split off in any order and with a compound of the general formula III
  • R 13 represents a hydrogen atom or a CrC 5 acyl group and Ar has the meaning given in the general formula I, reacted, the radical R 13 then being split off in order to arrive at a compound of the formula I.
  • the compound of the general formula VI can optionally also be formed only as an intermediate product which, if desired, can be isolated or can also be produced only in situ. for example, it can be an acid chloride formed intermediately from a corresponding carboxylic acid. For example, a fluorine, chlorine or bromine atom or, if no intermediate acid chloride is formed, the mesylate residue or tosylate residue may be mentioned as escape groups.
  • glucocorticoid receptor The binding of the substances to the glucocorticoid receptor (GR) is checked with the aid of a recombinantly produced receptor. Cytosol preparations from Sf9 cells which had been infected with recombinant baculoviruses which code for the GR are used for the binding studies. Compared to the reference substance [ 3 H] -dexamethasone, the substances show a high to very high affinity for GR.
  • these compounds show affinities for MR in the mineral corticqid receptor (MR) binding test using cytosol preparations from Sf9 cells which were infected with baculoviruses coding for the MR and with [ 3 H] aldosterone as reference substance.
  • MR mineral corticqid receptor
  • GR-mediated inhibition of the transcription of cytokines, adhesion molecules, enzymes and other pro-inflammatory factors is regarded as an essential molecular mechanism for the anti-inflammatory effect of glucocorticoids. This inhibition is caused by an interaction of the GR with other transcription factors, e.g. AP-1 and NF-kappa- B, (for an overview see Cato, AGB and Wade E, BioEssays 18, 371-378 1996).
  • the compounds of the general formula I according to the invention inhibit the secretion of the cytokine IL-8 triggered by lipopolysacchard (LPS) in the human monocyte cell line THP-1.
  • LPS lipopolysacchard
  • the concentration of the cytokines in the supernatant was determined using commercially available ELISA kits.
  • the anti-inflammatory activity of the compounds of the general formula I were tested in animal experiments by testing in croton oil-induced inflammation in the rat and the mouse (J. Exp. Med. (1995), 182, 99-108).
  • croton oil was applied topically to the ears in ethanolic solution.
  • the test substances were also applied topically or systemically at the same time or two hours before the croton oil.
  • the ear weight as a measure of the inflammatory edema
  • the peroxidase activity as a measure of the immigration of granulocytes
  • the Elastase activity measured as a measure of the immigration of neutrophil granulocytes.
  • the compounds of the general formula I inhibit the three above-mentioned inflammation parameters in this test both after topical and after systemic application.
  • glucocorticoid therapy One of the most common undesirable effects of glucocorticoid therapy is the so-called "steroid diabetes" [cf. Hatz, HJ, Glucocorticoide: Immunological basics, pharmacology and therapy guidelines, Horschafliche Verlagsgesellschaft mbH, Stuttgart, 1998].
  • the reason for this is the stimulation of gluconeogenesis in the liver by induction of the enzymes responsible for this and by free amino acids that result from the breakdown of proteins (catabolic effect of the glucocorticoids).
  • a key enzyme of the catabolic metabolism in the liver is tyrosine aminotranferase (TAT).
  • TAT tyrosine aminotranferase
  • the activity of this enzyme can be determined photometrically from liver homogenates and is a good measure of the undesirable metabolic effects of the glucocorticoids.
  • the animals are sacrificed 8 hours after the administration of the test substances, the liver is removed and the TAT activity in the Homogenate measured.
  • the compounds of the general formula I do not induce the tyrosine aminotransferase, or do so only to a small extent, in which they are anti-inflammatory.
  • the new compounds of general formula I have the following properties compared to the steroidal glucocorticoids used hitherto:
  • Non-steroidal structure ie the substances are still effective in patients who, due to an allergic reaction to the steroid basic structures of conventional glucocorticoids, are no longer accessible to them with therapy (cf.Lutz, ME, el-Azhary RA, Mayo Clin. Proc. 72 , 1141-1144, 1997), similarly good anti-inflammatory activity with low metabolic activity
  • the compounds of general formula I according to the invention can be used as medicaments for the treatment or prophylaxis of the following disease states in mammals and humans:
  • the term “DISEASE” stands for the following indications:
  • Lung diseases that are associated with inflammatory, allergic and / or proliferative processes - Chronic obstructive lung diseases of any genesis, especially
  • Kidney diseases associated with inflammatory, allergic and / or proliferative processes are associated with inflammatory, allergic and / or proliferative processes:
  • liver diseases associated with inflammatory, allergic and / or proliferative processes are included in the liver diseases associated with inflammatory, allergic and / or proliferative processes.
  • acute hepatitis of various origins e.g. viral, toxic, drug-induced - chronically aggressive and / or chronically intermittent hepatitis
  • Gastroenteritis of a different origin e.g. indigenous sprue (ix) proctological diseases associated with inflammatory, allergic and / or proliferative processes:
  • Severe shock conditions e.g. anaphylactic shock, systemic inflammatory response syndrome (SIRS)
  • SIRS systemic inflammatory response syndrome
  • adrenal insufficiency e.g. Addison's disease, autoimmune adrenalitis, post-infectious, tumors, metastases etc.
  • congenital secondary adrenal insufficiency e.g. congenital
  • the suitable dose for the therapeutic effects in the abovementioned disease states is different and depends, for example, on the potency of the compound of the general formula I, the host, the mode of administration and the type and severity of the conditions to be treated, and the use as a prophylactic or therapeutic agent.
  • the invention further provides
  • Compounds or their mixture and at least one pharmaceutical auxiliary and / or carrier comprises.
  • the daily doses comprise a range from 1 ⁇ g to 100,000 ⁇ g of the compound according to the invention per kg of body weight.
  • a recommended daily dose is in the range of 1 ⁇ g to 100,000 ⁇ g per kg body weight.
  • a dose of 10 to 30,000 ⁇ g per kg body weight is preferred, more preferably a dose of 10 to 10,000 ⁇ g per kg body weight.
  • this dose is conveniently administered several times a day.
  • acute shock e.g. anaphylactic shock
  • single doses can be given that are clearly above the doses mentioned above.
  • the pharmaceutical preparations based on the new compounds are formulated in a manner known per se by processing the active substance with the carrier substances, fillers, disintegrants, binders, humectants, lubricants, absorbents, diluents, flavoring agents, colorants, etc. customary in galenics and converted into the desired application form. It is made to Remington's Pharmaceutical Science, 15 tn ed. Mack Publishing Company, pointing East Pennsylvania (1980).
  • Tablets, coated tablets, capsules, pills, powders, granules, pastilles, suspensions, emulsions or solutions are particularly suitable for oral administration.
  • Appropriately prepared crystal suspensions can be used for intra-articular injection.
  • Aqueous and oily injection solutions or suspensions and corresponding depot preparations can be used for intramuscular injection.
  • the new compounds in the form of suppositories, capsules, solutions (for example in the form of clysms) and ointments can be used both for systemic and for local therapy.
  • the pulmonary application of the new compounds can be used in the form of aerosols and inhalants.
  • the new compounds can be used as drops, ointments and tinctures in appropriate pharmaceutical preparations for local use on the eyes, external auditory canal, middle ear, nasal cavity and paranasal sinuses.
  • formulations in gels, ointments, fatty ointments, creams, pastes, powder, milk and tinctures are possible.
  • the dosage of the compounds of the general formula I should be 0.01% to 20% in these preparations in order to achieve a sufficient pharmacological effect.
  • the invention also encompasses the compounds of general formula I according to the invention as therapeutic active ingredients.
  • the invention furthermore relates to the compounds of the general formula I according to the invention as a therapeutic active substance together with pharmaceutically acceptable and acceptable excipients and carriers.
  • the invention also comprises a pharmaceutical composition which contains one of the pharmaceutically active compounds according to the invention or a mixture thereof and a pharmaceutically acceptable salt or pharmaceutically acceptable excipients and carriers.
  • a solution of 8.04 ml of 2-diethylphosphono-2-ethoxyacetic acid ethyl ester in 40 ml of tetrahydrofuran is mixed with ice cooling within 16 minutes with 16.5 ml of a 2 M solution of lithium diisopropylamide in tetrahydrofuran-heptane toluene and 30 minutes at 0 ° C stirred.
  • a solution of 5.2 g of 2- (5-fluor-2-methylphenyI) -2-methylpropionaldehyde in 30 ml of tetrahydrofuran is added dropwise at 0 ° C. within 30 minutes.
  • 6- [4- (5-Fluoro-2-methylphenyl) -4-methyl-2-oxovaleroylamino] -4-methyl-2,3-benzoxazin-1-one was analogous to 5- [4- (5-fluoro 2-methylphenyl) -4-methyl-2-oxovaleroylamino] phthalide using 4- (5-fluoro-2-methylphenyl) -4- methyl-2-oxovaleric acid and 6-amino-2,3-benzoxazin-1-one obtained, mp. 186 ° C.
  • 6- [4- (2-Chloro-5-fluorophenyl) -4-methyl-2-oxovaIeroylamino] -4-methyl-2,3-benzoxazin-1-one becomes analogous to 5- [4- (5-fluor -2-methylphenyl) -4-methyl-2-oxovaleroylaminojphthalide obtained from 4- (2-chloro-5-fluorophenyl) -4-methyl-2-oxovaleric acid and 6-amino-2,3-benzoxazin-1-one, mp . 198-199 ° C.
  • Example 2 was obtained analogously to Example 1 from 6- [4- (2-chloro-5-fluorophenyl) -4-methyl-2-oxovaleroylamino] -2,3-benzoxazin-1-one, mp. 201-203 ° C.
  • the enantiomer mixture from Example 3 is separated by chromatography on a chiral support material (CHIRALPAK AD®, DAICEL) with hexane / ethanol (19: 1, vv). The following is obtained from 190 mg of racemate:
  • 2- (3-fluorophenyl) -2-methylpropionitrile Analogously to the process described for 2- (5-fluoro-2-methylphenyl) -2-methylpropionitrile, 2- (3-fluorophenyl) -2-methylpropionitrile is synthesized, b.p. 102-103 ° C70.029 hPa.
  • ethyl 4- (3-fluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvalerate are dissolved in 20 ml of trifluoroacetic acid and at 0 ° C with 0.84 ml of 100 percent. Nitric acid added. After 3 hours at 0 ° C. and 16 hours at room temperature, the mixture is poured onto ice, the crystals are filtered off with suction, washed with water and dried. By recrystallization from hexane, 2.5 g of ethyl 4- (5-fluoro-2-nitrophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvalerate, mp. 66-67 ° C., are obtained. After chromatography on silica gel with hexane, the mother liquor
  • Ethyl acetate (8: 1) as the first fraction a further 500 mg of 4- (5-fluor-2-nitrophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleric acid ethyl ester and as the second fraction 800 mg of 4- (3-fluoro- 4-nitrophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleric acid ethyl ester as an oil.
  • Example 4 is obtained analogously to Example 4 from 4- (5-fluoro-2-nitrophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleric acid and 6-amino-2,3-benzoxazin-1-one, mp. 208-210 ° C.
  • Example 4 is obtained analogously to Example 4 from 4- (3-fluoro-4-nitrophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleric acid and 5-aminophthalide, mp. 188-189 ° C.
  • Example 4 is obtained analogously to Example 4 from 4- (3-fluoro-4-nitrophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleric acid and 6-amino-2,3-benzoxazin-1-one, mp. 236-237 ° C.
  • Triethylamine added at 0 ° C. After 10 min at room temp. become 10.6 mL
  • the combined extracts are dried (Na2SO 4 ) and i. Vak. concentrated.
  • the residue is taken up in 8 mL DMF and treated with 0.42 mL (6.8 mmol) methyl iodide and 2.21 g (6.8 mmol) cesium carbonate. After 5 h at room temp. the mixture is diluted with 600 mL MTBE, with 10 percent. Sulfuric acid and sat. Washed NaCI, dried (Na 2 S0 4 ) and i. Vak. concentrated. Column chromatography on silica gel with hexane-ethyl acetate yields 0.9 g of product.
  • the mixture is diluted with 150 mL MTBE, with a solution of 1.2 g NaHCOs and 4.0 g Na 2 S ⁇ 3 in 50 mL water, sat. NaHCO 3 and sat. Washed NaCI, dried (Na 2 SO 4 ) and i. Vak. concentrated.
  • the residue 250 mg is taken up in 16 mL THF-EtOH (1: 1) and mixed with 3.9 mL (3.9 mmol) of a 1 M sodium hydroxide solution. After 30 minutes, the batch is i. Vak. concentrated, diluted with 20 mL water and washed with MTBE. The aqueous phase is with 10 percent.
  • the enantiomer mixture from Example 9 is separated by chromatography on a chiral support material (CHIRALPAK AD®, DAICEL) with hexane / ethanol (95: 5, vv). The following is obtained from 830 mg of racemate:
  • Ethyl 2-hydroxy-4-methyl-4- (4-trifluoromethylphenyl) valerate 1.72 g (6.0 mmol) ethyl 4-methyl-4- (4-trifluomethylphenyl) -2-pentenoate are dissolved in ethyl acetate in the presence of 0.17 g 10 proc. Palladium / activated carbon catalyst stirred for 15 h in a hydrogen atmosphere (1 atm). The mixture is filtered through Celite and i. Vak. concentrated: 1.72 g of 4-methyl-4- (4-trifluomethylphenyl) valeric acid ethyl ester. 0.57 g (2.0 mmol) of this is dissolved in 7 mL THF and at -78 ° C with 5.6 mL (2.8 mmol)
  • Example 13 is a by-product of the synthesis of Example 12.
  • 1 H-NMR (CDCIs), ⁇ (ppm) 1.41 (s, 3H), 1.44 (s, 3H), 2.44 (d, 1H), 2.60 (s, 3H), 2.80 (br. S, 1H ), 2.89 (d, 1 H), 6.53 (dd, 1 H), 6.92 (m, 2H), 7.66 (dd, 1 H), 8.24 (d, 1 H), 8.35 (d, 1 H), 8.70 (br.s, 1 H).
  • 2- (5-fluoro-2-methylphenyl) -2-methylpropionaldehyde is obtained as a colorless oil, bp 80 ° C / 0.05 hPa.
  • the enantiomer mixture from Example 14 is separated by chromatography on a chiral support material (CHIRALPAK AD®, DAICEL) with hexane / ethanol (19: 1, v). The following is obtained from 100 mg of racemate:
  • 6- [4-Methyl-4- (3-methyl-2-nitrophenyl) -2-oxovaleroylamino] -4-methyl-2,3-benzoxazin-1-one is analogous to 5- [4- (5-fluoro- 2-methylphenyl) -4-methyl-2-oxovaleroylamino] phthalide obtained from 4-methyl-4- (3-methyl-2-nitrophenyl) -2-oxovaleric acid and 6-amino-2,3-benzoxazin-1-one, mp . 184-187 ° C.
  • Example 18 was obtained analogously to Example 1 from 6- [4-methyl-4- (3-methyl-2-nitrophenyl) -2-oxovaleroylamino] -4-methyl-2,3-benzoxazin-1 -one, mp 201- 203 ° C.
  • Example 18
  • Example 22 is obtained analogously to Example 20 from 5- [4- (2-amino-5-fluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] phthalide, mp. 125 ° C.
  • Example 22 is obtained analogously to Example 20 from 5- [4- (2-amino-5-fluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] phthalide, mp. 125 ° C.
  • Example 22 is obtained analogously to Example 20 from 5- [4- (2-amino-5-fluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] phthalide, mp. 125 ° C.
  • Example 22 is obtained analogously to Example 20 from 5- [4- (2-amino-5-fluorophenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] phthalide, mp. 125 ° C.
  • the enantiomer mixture from Example 23 is separated by chromatography on a chiral support material (CHIRALPAK AD®, DAICEL) with hexane / ethanol (93: 7, vv).
  • Example 25 is analogous to Example 24 starting from the corresponding (-) - 6- [4- (2-bromo-3-methoxyphenyl) -2-hydroxy-4-methyl-2-trifluoromethylvaleroylamino] - 4-methyl-2, 3-benzoxazin-1-one produced.
  • the enantiomer mixture from Example 28 is separated by chromatography on a chiral support material (CHIRALPAK AD®, DAICEL) with hexane / ethanol (9: 1, vv).
  • a chiral support material CHIRALPAK AD®, DAICEL
  • the following is obtained from 300 mg of racemate: (-) - 6- ⁇ 3- [4- (2-Chloro-5-fluorophenyl) tetrahydropyran-4-yl] -2-hydroxy-2-trifluoromethylpropionylamino ⁇ -4-methyl-2,3-benzoxazin-1 - on as the first fraction 129 mg, mp.
  • the potency of the anti-inflammatory is determined by inhibiting the secretion of the cytokine IL-8 in a cell test.
  • the compounds of the general formula I according to the invention inhibit the secretion of the cytokine IL-8 triggered by lipopolysacchard (LPS) in the human monocyte cell line THP-1.
  • LPS lipopolysacchard
  • the concentration of the cytokines in the supernatant was determined using commercially available ELISA kits.
  • the compounds of formula 1 show a high to very high potency and effectiveness in inhibition (see Table 10).
  • the anti-inflammatory activity of the compounds of the general formula I were tested in animal experiments in croton oil-induced inflammation in the rat and the mouse (J. Exp. Med. (1995), 182, 99-108).
  • croton oil was applied topically to the ears in ethanolic solution.
  • the test substances were applied systemically two hours before the croton oil. After 16-24 hours, the ear weight was measured as a measure of the inflammatory edema.
  • the compounds of formula 1 show a comparable and sometimes stronger inhibition of the inflammation induced by croton oil to the standard (prednisolone) (see Table 11).
  • TAT tyrosine aminotranferase
  • the induction factor stands for the corresponding n-fold increase in tyrosine aminotranferase enzyme activity in treated animals compared to untreated animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP01960536A 2000-07-28 2001-07-23 Nichtsteroidale entzündungshemmer Withdrawn EP1309571A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10038639A DE10038639A1 (de) 2000-07-28 2000-07-28 Nichtsteroidale Entzündungshemmer
PCT/EP2001/008501 WO2002010143A1 (de) 2000-07-28 2001-07-23 Nichtsteroidale entzündungshemmer
DE10038639 2003-10-06

Publications (1)

Publication Number Publication Date
EP1309571A1 true EP1309571A1 (de) 2003-05-14

Family

ID=7651697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01960536A Withdrawn EP1309571A1 (de) 2000-07-28 2001-07-23 Nichtsteroidale entzündungshemmer

Country Status (27)

Country Link
US (3) US6777409B2 (enExample)
EP (1) EP1309571A1 (enExample)
JP (1) JP2004505068A (enExample)
KR (1) KR20030019626A (enExample)
CN (2) CN1915231A (enExample)
AU (2) AU2001282009B2 (enExample)
BG (1) BG107488A (enExample)
BR (1) BR0112786A (enExample)
CA (1) CA2417444A1 (enExample)
CZ (1) CZ2003216A3 (enExample)
DE (1) DE10038639A1 (enExample)
EA (1) EA005926B1 (enExample)
EE (1) EE200300043A (enExample)
HR (1) HRP20030148A2 (enExample)
HU (1) HUP0301344A3 (enExample)
IL (1) IL154143A0 (enExample)
MX (1) MXPA02012933A (enExample)
NO (1) NO20030406L (enExample)
NZ (1) NZ523822A (enExample)
PE (1) PE20020230A1 (enExample)
PL (1) PL366336A1 (enExample)
SK (1) SK812003A3 (enExample)
TW (1) TWI282336B (enExample)
UA (1) UA77657C2 (enExample)
WO (1) WO2002010143A1 (enExample)
YU (1) YU5503A (enExample)
ZA (1) ZA200301639B (enExample)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238707B2 (en) 2000-07-28 2007-07-03 Schering Ag Substituted pentanols, a process for their production and their use as anti-inflammatory agents
DE10346940B3 (de) * 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
PT1482925E (pt) * 2002-03-11 2007-04-30 Bayer Schering Pharma Ag 5-(2-hidroxi-3-'1-(3-trifluorometilfenil)-ciclopropil]-propionilamino-ftalida e compostos relacionados com actividade de modulação do receptor da progesterona para utilização no controlo de fertilidade e terapia de substituição hormonal
EP1344776A1 (en) * 2002-03-11 2003-09-17 Schering Aktiengesellschaft 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
AU2003230700A1 (en) 2002-03-26 2003-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2298508T3 (es) 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
DE10215316C1 (de) * 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US6897224B2 (en) * 2002-04-02 2005-05-24 Schering Ag Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2006504678A (ja) 2002-08-21 2006-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
RS20050174A (sr) * 2002-08-29 2007-06-04 Boehringer Ingelheim Pharmaceuticals Inc., Derivati 3-(sulfonamidoetil)-indola za primenu kao mimetici glukokortikoida u lečenju zapaljenskih,alergijskih i proliferativnih oboljenja
JP4373926B2 (ja) 2003-01-03 2009-11-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド １−プロパノール及び１−プロピルアミン誘導体ならびにグルココルチコイドリガンドとしての使用
WO2004071389A2 (en) * 2003-02-15 2004-08-26 Glaxo Group Limited Non-steroidal infalmmation inhibitors
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
CA2531060A1 (en) * 2003-07-01 2005-01-13 Schering Aktiengesellschaft Heterocyclically-substitued pentanol derivatives, process for their production and their use as anti-inflammatory agents
US20050090559A1 (en) * 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
DE102004017662B3 (de) * 2004-04-05 2005-12-08 Schering Ag Mehrfach substituierte Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
SI1670458T1 (sl) 2003-10-08 2007-06-30 Bayer Schering Pharma Ag Tetrahidronaftalenski derivati, postopek za njihovo pripravo in njihova uporaba kot antiinflamatoriki
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE10347385A1 (de) * 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP1675839B1 (en) 2003-10-16 2007-07-11 Boehringer Ingelheim Pharmaceuticals Inc. Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US20080153859A1 (en) * 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006000401A1 (en) * 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) * 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US20060084652A1 (en) * 2004-09-09 2006-04-20 Stefan Baeurle Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE102004044680B3 (de) * 2004-09-09 2006-06-08 Schering Ag Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US20060167025A1 (en) * 2004-12-22 2006-07-27 Markus Berger Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
DE102004063227A1 (de) * 2004-12-22 2006-07-06 Schering Ag Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
WO2006071609A2 (en) * 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2006213674A (ja) * 2005-02-07 2006-08-17 Ube Ind Ltd ４−ホルミルテトラヒドロピラン化合物の製法
US20060229305A1 (en) * 2005-03-22 2006-10-12 Markus Berger Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE102005014089A1 (de) * 2005-03-22 2006-09-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
JP2006265173A (ja) * 2005-03-24 2006-10-05 Sumitomo Chemical Co Ltd グルココルチコイド受容体リガンド結合ドメインとリガンドとの複合体を含む結晶
DE102005017326A1 (de) * 2005-04-14 2007-03-29 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005017286B3 (de) * 2005-04-14 2006-12-28 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102005018026B4 (de) * 2005-04-14 2006-12-21 Schering Ag Substituierte Styrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005017301A1 (de) * 2005-04-14 2006-10-19 Schering Ag Substituierte Chromanderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
CN101166722A (zh) 2005-04-29 2008-04-23 惠氏公司 制备3,3-二取代的羟吲哚和硫代羟吲哚的方法
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7408060B2 (en) * 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
AU2006324097B2 (en) * 2005-12-09 2011-08-25 F. Hoffmann-La Roche Ag Glucocorticoid receptor modulators as antiinflammatory agents
BRPI0619519A2 (pt) * 2005-12-09 2011-10-04 Hoffmann La Roche compostos de propionamida como agentes antiinflamatórios
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1834948A1 (de) * 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EA200801997A1 (ru) * 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
CA2671990A1 (en) 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
EP2279777A2 (en) 2007-01-10 2011-02-02 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP1958934A1 (en) * 2007-02-16 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
EP2062880A1 (en) 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
DE102007058747A1 (de) * 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
MX2010013095A (es) 2008-06-06 2010-12-21 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
ES2535736T3 (es) 2008-06-10 2015-05-14 Novartis Ag Derivados de pirazina como bloqueadores de los canales de sodio epitelial
EP2149558A1 (en) 2008-07-21 2010-02-03 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PL2379507T3 (pl) 2008-12-30 2014-03-31 Pulmagen Therapeutics Inflammation Ltd Związki sulfonamidu do leczenia zaburzeń układu oddechowego
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011016050A2 (en) 2009-07-31 2011-02-10 Cadila Healthcare Limited Novel compounds as modulators of glucocorticoid receptors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
US9085560B2 (en) 2009-08-17 2015-07-21 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
WO2013032942A1 (en) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
RU2483723C1 (ru) * 2012-04-25 2013-06-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения эндокринной офтальмопатии
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US10155001B2 (en) 2013-06-14 2018-12-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) RAC1 inhibitors for inducing bronchodilation
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
MX2018008849A (es) 2016-01-19 2019-01-31 Corcept Therapeutics Inc Diagnostico diferencial de sindrome de cushing ectopico.
EP3417056A1 (en) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Improved influenza b virus replication for vaccine development
PT3600282T (pt) 2017-03-31 2025-11-05 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides para tratar cancro cervical
EP3641780B1 (en) 2017-06-20 2025-09-10 Corcept Therapeutics Incorporated Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
EP3569228A1 (en) 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
DK3700513T3 (da) * 2017-10-27 2022-11-28 Association Pour La Rech A Ligbmc Ari Ikke-steroide selektive glucocorticoidreceptor-agonistiske modulatorer (segram) og anvendelser deraf
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
KR20220019015A (ko) 2019-06-10 2022-02-15 노파르티스 아게 Cf, copd, 및 기관지확장증 치료를 위한 피리딘 및 피라진 유도체
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
AU2021400069A1 (en) 2020-12-18 2023-07-06 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
JP3464405B2 (ja) * 1999-02-18 2003-11-10 阪神化成工業株式会社 多層薄肉容器

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0210143A1 *

Also Published As

Publication number Publication date
EA005926B1 (ru) 2005-08-25
HRP20030148A2 (en) 2005-10-31
CN1444570A (zh) 2003-09-24
US6777409B2 (en) 2004-08-17
US7129270B2 (en) 2006-10-31
ZA200301639B (en) 2004-06-22
TWI282336B (en) 2007-06-11
BR0112786A (pt) 2003-07-01
PE20020230A1 (es) 2002-03-17
EA200300105A1 (ru) 2003-06-26
NO20030406D0 (no) 2003-01-27
BG107488A (bg) 2003-07-31
NZ523822A (en) 2006-01-27
US20040254249A1 (en) 2004-12-16
CA2417444A1 (en) 2002-02-07
YU5503A (sh) 2006-05-25
KR20030019626A (ko) 2003-03-06
HUP0301344A2 (hu) 2003-08-28
JP2004505068A (ja) 2004-02-19
NO20030406L (no) 2003-03-27
EE200300043A (et) 2004-10-15
UA77657C2 (en) 2007-01-15
WO2002010143A1 (de) 2002-02-07
SK812003A3 (en) 2003-07-01
CN1915231A (zh) 2007-02-21
US20020077356A1 (en) 2002-06-20
AU8200901A (en) 2002-02-13
US20060040933A1 (en) 2006-02-23
AU2001282009B2 (en) 2006-06-22
PL366336A1 (en) 2005-01-24
HUP0301344A3 (en) 2004-10-28
IL154143A0 (en) 2003-07-31
CZ2003216A3 (cs) 2003-05-14
US7166592B2 (en) 2007-01-23
DE10038639A1 (de) 2002-02-21
MXPA02012933A (es) 2003-09-22

Similar Documents

Publication Publication Date Title
EP1309571A1 (de) Nichtsteroidale entzündungshemmer
EP1133486B1 (de) Nichtsteroidale entzündungshemmer
EP1572671A1 (de) Nichtsteroidale entzündungshemmer
EP1844039B1 (de) 5-substituierte chinolin- und isochinolin-derivate; ein verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
DE102004063227A1 (de) Tricylische Aminoalkohole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005017286B3 (de) Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
WO2006027236A1 (de) Alkyliden-tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
DE10346939A1 (de) Heterocyclisch substituierte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102004017662B3 (de) Mehrfach substituierte Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005014090A1 (de) 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005020331A1 (de) 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005018024A1 (de) Benzazepine als neue Glucocorticoidmimetika, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10330358A1 (de) Heterozyklisch substituierte Pentanol-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005018025A1 (de) Mehrfach substituierte bizyklische Systeme, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
WO2006108711A1 (de) Substituierte chromanderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
WO2005116015A1 (de) Chromanol-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021219

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SCHOTTELIUS, ARNDT

Inventor name: SCHAECKE, HEIKE

Inventor name: HENNEKES, HARTWIG

Inventor name: KROLIKIEWICZ, KONRAD

Inventor name: SKUBALLA, WERNER

Inventor name: DROESCHER, PETER

Inventor name: REHWINKEL, HARTMUT

Inventor name: BUCHMANN, BERND

Inventor name: SCHMEES, NORBERT

Inventor name: LEHMANN, MANFRED

Inventor name: JAROCH, STEFAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20071214

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091126